Caricamento...
A Phase II Dose Titration Study of Thalidomide for Cancer-Associated Anorexia
CONTEXT: Sixty-five percent of people with advanced cancer suffer from loss of appetite. Several inflammatory cytokines appear to cause appetite loss in animal models. Thalidomide is an immunomodulatory drug that has been associated with improved appetite in those with HIV infections, and in cancer....
Salvato in:
| Pubblicato in: | J Pain Symptom Manage |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2011
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4496946/ https://ncbi.nlm.nih.gov/pubmed/21640548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jpainsymman.2011.03.007 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|